Barclays maintains Doximity at Equal-Weight, raises price target to $30 from $27

Barclays kept Doximity at Equal-Weight, raising its price target to $30 from $27. This implies a 7.5% downside from the Nov 10 close of $32.42. Recent analyst price targets for Doximity range from $32 to $41.

Original reporting
Published Nov 11, 2026, 3:18 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 11, 2026, 3:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Barclays maintains Doximity at Equal-Weight, raises price target to $30 from $27 — source image
Decision brief

The 30-second read

Low
01

Why it matters

The target increase may attract short-term buying interest but lacks a catalyst beyond the rating change.

02

Market read

A modest analyst upgrade with limited trading impact; useful for short-term sentiment monitoring.

03

What to watch

Recent earnings beat or user growth trends not mentioned could justify the upgrade.

Relevance 4/10Novelty 3/10Timing: same day

Background

Barclays' analyst note updates Doximity's valuation metrics.

Market effects

None significant; Doximity operates in digital health recruitment.

US-focused, minimal broader impact.

Limited to investors tracking analyst coverage.

Counterpoint

Target raise may be premature without fresh earnings data; price could stall.

Key entities

  • Barclays

    Equity research firm providing the price target upgrade.

  • Doximity

    Digital platform for medical professionals, ticker DOX.

Related articles

Med

Doximity: 3 Key Takeaways for Long-Term Investors

Doximity updated its full-year revenue guidance to $678M-$683M, citing steady demand and pricing discipline. The company highlights operating efficiency and AI investments as key drivers. According to CFO Matthew Sonefeldt, these factors support continued growth amid technological shifts.

$DOCSMedAI 8/10

DOCS Q3 CY2026 deep dive: AI-driven product expansion meets margin compression

Doximity reported Q3 CY2026 revenue of $174.5M, beating estimates by 2%, with adjusted EPS in line. Adjusted EBITDA exceeded expectations by 9.1%, but operating margin fell to 25.2% from 37.8% YoY. The company raised full-year revenue guidance to $680.5M and maintained EBITDA guidance at $321M. AI product adoption surged, with 16 of the top 20 pharma companies using AI Search. New health system clients and partnerships were added, driving growth.

$DOCSMedAI 8/10

Doximity Q2 Earnings Call Highlights

Doximity (DOCS) reported Q2 earnings, raising fiscal 2027 revenue guidance to $678M-$683M. AI Search revenue is expected to ramp gradually. Health system clients grew to 190, including 10 of the top 20 hospitals. Non-GAAP EPS was $0.36, with $713M in cash. Management discussed AI monetization and adoption challenges.

$DOCSMedAI 8/10

Doximity Earnings Call Highlights AI Growth and Guidance

Doximity (DOCS) reported Q2 revenue of $175M (+4% YoY), beating expectations. Adjusted EBITDA was $89M (51% margin), exceeding guidance. AI initiatives drove growth, with expanded health-system adoption and improved AI economics. Revenue guidance raised to $678M-$683M for 2027. Challenges include modest growth, margin pressure, and AI-search return uncertainty.